Morgan Stanley analyst Terence Flynn raised the firm’s price target on Johnson & Johnson to $200 from $197 and keeps an Equal Weight rating on the shares after the company posted a slight Q4 beat and issued first time 2026 guidance, with revenue coming in above expectations and adjusted EPS bracketing consensus. Management also highlighted a path to double-digit growth by the end of the decade, the analyst noted.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target raised to $220 from $205 at Stifel
- Johnson & Johnson price target raised to $250 from $240 at Goldman Sachs
- Johnson & Johnson price target raised to $221 from $220 at BofA
- Johnson & Johnson price target raised to $250 from $232 at Citi
- Johnson & Johnson price target raised to $240 from $230 at Wells Fargo